Table 1.
NBL4 and D4Z4 methylation stratified by PCa patient characteristics
| Characteristics | N (%) | NBL4, β (SD) | P value | D4Z4, β (SD) | P value |
|---|---|---|---|---|---|
| Age at diagnosis, years | |||||
| <55 | 66 (8.3) | 79.0 (2.6) | 68.5 (4.8) | ||
| 55–65 | 346 (43.5) | 78.6 (3.1) | 68.4 (4.1) | ||
| >65 | 383 (48.2) | 78.7 (3.0) | 0.493 | 69.2 (4.8) | 0.022 |
| Body mass index at diagnosis, kg/m2 | |||||
| <25 | 115 (14.5) | 78.9 (2.8) | 68.7 (4.3) | ||
| 25–29.99 (overweight) | 287 (36.1) | 78.8 (2.9) | 68.9 (4.4) | ||
| ≥30 (obese) | 252 (31.7) | 78.3 (3.0) | 68.5 (4.7) | ||
| Unknown | 141 (17.7) | 79.0 (3.4) | 0.787 | 69.0 (4.5) | 0.882 |
| Smoking status at diagnosis | |||||
| Non-smoker | 354 (44.5) | 78.7 (3.0) | 69.0 (4.4) | ||
| Former smoker | 364 (45.8) | 78.7 (3.0) | 68.7 (4.6) | ||
| Current smoker | 69 (8.7) | 78.7 (2.9) | 68.3 (4.7) | ||
| Unknown | 8 (1.0) | 77.3 (2.2) | 0.725 | 68.8 (5.1) | 0.473 |
| D’Amico risk group | |||||
| Low | 260 (32.9) | 78.6 (3.0) | 69.0 (4.6) | ||
| Intermediate | 217 (27.5) | 78.9 (3.0) | 68.5 (4.3) | ||
| High | 313 (39.6) | 78.7 (3.0) | 0.828 | 68.8 (4.6) | 0.525 |
| Total Gleason score | |||||
| ≤6 | 274 (34.5) | 78.5 (3.0) | 69.0 (4.5) | ||
| 7 | 240 (30.2) | 78.8 (3.0) | 68.5 (4.2) | ||
| ≥8 | 281 (35.3) | 78.7 (3.0) | 0.423 | 68.8 (4.7) | 0.403 |
| Clinical tumor stage | |||||
| T1 | 572 (71.9) | 78.7 (3.0) | 68.7 (4.4) | ||
| T2 | 54 (6.8) | 78.7 (3.1) | 68.6 (4.9) | ||
| T3–T4 | 169 (21.3) | 78.7 (2.9) | 0.810 | 69.2 (4.8) | 0.311 |
| PSA at diagnosis | |||||
| <10 ng/ml | 633 (79.6) | 78.7 (3.0) | 68.8 (4.5) | ||
| 10–20 ng/ml | 80 (10.1) | 78.5 (3.3) | 68.7 (4.3) | ||
| >20 ng/ml | 82 (10.3) | 78.5 (3.0) | 0.371 | 68.4 (5.0) | 0.244 |
| Initial primary treatment | |||||
| Radical prostatectomy | 375 (47.2) | 78.7 (3.0) | 68.8 (4.3) | ||
| Radiotherapy | 133 (16.7) | 78.9 (2.8) | 68.6 (4.3) | ||
| Surveillance or unknown | 268 (33.7) | 78.5 (3.1) | 68.7 (4.9) | ||
| Other treatment | 19 (2.4) | 80.0 (2.9) | 0.803 | 70.0 (4.5) | 0.763 |